Clinical spectrum of acute severe ulcerative colitis in the biologic era: a prospective cohort study from India
Authors:
- Arshdeep SinghASArshdeep Singh
- Mayur LuthraMLMayur Luthra
- Arshia BhardwajABArshia Bhardwaj
- Ramit MahajanRMRamit Mahajan
- Riya SharmaRSRiya Sharma
- Dharmatma SinghDSDharmatma Singh
- Devanshi JainDJDevanshi Jain
- Omesh GoyalOGOmesh Goyal
- Varun MehtaVMVarun Mehta
- Kirandeep KaurKKKirandeep Kaur
- Yogesh Kumar GuptaYGYogesh Kumar Gupta
- Vandana MidhaVMVandana Midha
Open Access
- 30 April 2026
- journal article
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 24 (2) , 236-247
Abstract
Background/Aims: Acute severe ulcerative colitis (ASUC) is a time-critical situation requiring urgent intervention. Limited data exist on the evolving clinical spectrum of ASUC in the era of advanced therapies. Methods: This prospective real-world observational cohort study included 145 adult patients hospitalized with ASUC between January 2020 and June 2024. ASUC was defined by the modified Truelove and Witts criteria. Demographics and disease characteristics, including disease severity, probable precipitating factors, and corticosteroid failure rates, were recorded. Results: The median age of patients was 36 years (interquartile range, 26–48.5 years) with 63 females (43.4%). Most patients had left-sided colitis (53.1%). The median disease duration was 1 year (IQR, 0.5–3 years), with 91 patients (62.7%) presenting with ASUC within the first year of diagnosis of ulcerative colitis. One-third of the patients had previous exposure to biologics and small molecules. The most commonly reported probable precipitants of ASUC were poor compliance with treatment (n = 43, 29.6%), antibiotic use (n = 35, 24.1%), high perceived stress (n = 32, 22.1%), and Clostridioides difficile infection (n = 19, 13.1%). Forty patients (27.5%) were non-responders to intravenous corticosteroids (IVCS). Twenty-nine patients (20%) received medical rescue therapy (infliximab, n = 14 [48.27%], cyclosporine A, n = 6 [20.68%], and tofacitinib, n = 9 [31.03%]). Seven patients (4.82%; 4 after non-response to IVCS and 3 after non-response to medical rescue therapy) underwent colectomy. Conclusions: In this cohort of ASUC patients, poor treatment compliance, antibiotic use, stress, and C. difficile infection were common precipitants of flare-ups. Nearly one-third of patients required medical rescue therapy, and a small proportion ultimately underwent colectomy.Keywords
This publication has 44 references indexed in Scilit:
- Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trialThe Lancet Gastroenterology & Hepatology, 2024
- Systematic Review: Outcome Prediction in Acute Severe Ulcerative ColitisGastro Hep Advances, 2023
- Low prevalence of Clostridioides difficile infection in acute severe ulcerative colitis: A retrospective cohort study from northern IndiaIndian Journal of Gastroenterology, 2023
- Stress burden and neuroendocrine regulation of cytokine production in patients with ulcerative colitis in remissionPsychoneuroendocrinology, 2018
- Clostridium difficile infection in acute flares of inflammatory bowel disease: A prospective studyDigestive and Liver Disease, 2017
- Cyclosporine or infliximab as rescue therapy in severe refractory ulcerative colitis: Early and long-term data from a retrospective observational studyJournal of Crohn's and Colitis, 2012
- Long-term outcome in patients with ulcerative colitis treated with intravenous cyclosporine A is determined by previous exposure to thiopurinesJournal of Crohn's and Colitis, 2010
- The pattern and outcome of acute severe colitisJournal of Crohn's and Colitis, 2010
- The Effect of Acute Psychologic Stress on Systemic and Rectal Mucosal Measures of Inflammation in Ulcerative ColitisGastroenterology, 2006
- Prognosis of severe attacks in ulcerative colitis: effect of intensive medical treatmentDigestive and Liver Disease, 2004